Delcath Systems Schedules Conference Call to Report 2021 Second Quarter Financial Results

Rhea-AI Summary

Delcath Systems, Inc. (Nasdaq: DCTH) will host a conference call on August 10, 2021, at 8:30 AM ET to discuss its second-quarter results for the period ending June 30, 2021. The call will be accessible via phone and online. Delcath focuses on providing innovative treatments for rare liver cancers through its proprietary PHP system, which allows high-dose chemotherapy directly to the liver, minimizing systemic side effects. In Europe, the PHP system is marketed as CHEMOSAT, while in the U.S., it is under the name HEPZATO KIT.

Positive

• Focus on innovative treatment for rare liver cancers.
• Proprietary PHP system designed for targeted chemotherapy.
• Established presence in Europe with CHEMOSAT.

Negative

• No recent financial results disclosed prior to the conference call.

NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on August 10, 2021 at 8:30 AM Eastern Time to discuss results for its second quarter ended June 30, 2021.

Conference Call Information

To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.

Date: August 10, 2021
Time: 8:30 AM Eastern Time
Toll Free: 877-545-0523; Entry Code: 148562
International: 973-528-0016; Entry Code: 148562

The call will also be available over the Internet and accessible at: 

https://www.webcaster4.com/Webcast/Page/2475/42376

About Delcath Systems, Inc.

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company’s proprietary percutaneous hepatic perfusion (PHP) system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In the United States, the PHP system is being developed under the tradename HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), or HEPZATO, and is considered a combination drug and device product regulated by the United States Food and Drug Administration (FDA).

In Europe, the PHP system is regulated as a Class IIb medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used at major medical centers to treat a wide range of cancers of the liver. CHEMOSAT is being marketed under an exclusive licensing agreement with medac GmbH, a privately held multi-national pharmaceutical company headquartered in Germany that specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases.

Contact:

Delcath Investor Relations

Email: investorrelations@delcath.com

Hayden IR

James Carbonara 
(646)-755-7412 
james@haydenir.com

FAQ

When is Delcath Systems' conference call regarding Q2 results?

The conference call is scheduled for August 10, 2021, at 8:30 AM Eastern Time.

What is the focus of Delcath Systems, Inc.?

Delcath Systems focuses on interventional oncology, specifically treating primary and metastatic liver cancers.

What products does Delcath Systems offer?

Delcath offers the PHP system, marketed as HEPZATO KIT in the U.S. and CHEMOSAT in Europe.

How can investors participate in the conference call?

Investors can join the call by dialing 877-545-0523 (toll-free) or 973-528-0016 (international) with entry code 148562.